Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study
Free accessOtherFirst published online October, 2009
Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study
Background: While preprocedural statin treatment for acute coronary syndrome (ACS) is widely regarded as beneficial, there has been no prospective randomized multicenter trial of patients with non-ST elevation ACS in the Japanese population to examine the efficacy of preprocedural aggressive statin use. The aim of this study was to confirm this effect by prospective randomized multicenter design.
Methods: Fifty patients who presented with non-ST elevation ACS were enrolled, and randomly assigned to aggressive statin administration before percutaneous coronary intervention (PCI). Troponin-T (TnT), creatine phosphokinase (CK), CK-myocardial band (CK-MB), high-sense C-reactive protein (hs-CRP), and brain natriuretic peptide (BNP) were measured at baseline and/ or after procedure.
Results: Three days after PCI, the statin group had significantly less CK elevation compared with the nonstatin group (84±17 IU/l versus 180±68 IU/l, respectively, p = 0.02). CK-MB elevation also tended to be lower in the statin group than in the nonstatin group (3.2±1.9 versus. 7.0±3.0, respectively, p = 0.07), as was BNP level (3.2±1.9 versus 7.0±3.0 pg/ml, respectively, p = 0.07). The change of serum LDL cholesterol was significantly correlated with CK (p = 0.01) and TnT (p = 0.02) at 1 day after PCI.
Conclusions: Aggressive statin usage before PCI to Japanese patients with non-ST elevation ACS appears to reduce myocardial damage after procedure. The degree of serum lipid level reduction may reflect the vulnerability of atheromatous plaques that could cause cardiac damage after PCI.
Chan, A.W., Bhatt, D.L., Chew, D.P., Quinn, M.J., Moliterno, D.J., Topol, E.J. et al. (2002) Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation105: 691-696.
2.
Chan, A.W., Bhatt, D.L., Chew, D.P., Reginelli, J., Schneider, J.P., Topol, E.J. et al. (2003) Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation107: 1750-1756.
3.
de Lemos, J.A., Blazing, M.A., Wiviott, S.D., Lewis, E.F., Fox, K.A., White, H.D. et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Jama292: 1307-1316.
4.
Dupuis, J., Tardif, J.C., Cernacek, P. and Theroux, P. ( 1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation99: 3227-3233.
5.
FRagmin and Fast Revascularisation during In Stability in Coronary artery disease Investigators. (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet354: 708-715.
6.
Hara, H., Nakamura, M., Yokouchi, I., Kimura, K., Nemoto, N., Ito, S. et al. (2007) Impact of Statin Therapy on Coronary Intervention for Non-ST Elevation Acute Coronary Syndrome With Decreased Low-Density Lipoprotein Cholesterol. J Cardiol49: 113-123.
7.
Herrmann, J., Lerman, A., Baumgart, D., Volbracht, L., Schulz, R., von Birgelen, C. et al. (2002) Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation106: 2180-2183.
8.
Ioannidis, J.P., Karvouni, E. and Katritsis, D.G. ( 2003) Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol42: 1406-1411.
9.
Jialal, I., Stein, D., Balis, D., Grundy, S.M., Adams-Huet, B. and Devaraj, S. ( 2001) Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation103: 1933-1935.
10.
Kluft, C., de Maat, M.P., Gevers Leuven., Potter, J.A., van Loon, B.J. and Mohrschladt, M.F. (1999) Statins and C-reactive protein. Lancet353: 1274.
11.
Lacoste, L., Lam, J.Y., Hung, J., Letchacovski, G., Solymoss, C.B. and Waters, D. ( 1995) Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation92: 3172-3177.
12.
Liao, J.K. ( 2007) Safety and Efficacy of Statins in Asians. Am J Cardiol99: 410-414.
13.
Notarbartolo, A., Davi, G., Averna, M., Barbagallo, C.M., Ganci, A., Giammarresi, C. et al. (1995) Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol15: 247-251.
14.
Okazaki, S., Yokoyama, T., Miyauchi, K., Shimada, K., Kurata, T., Sato, H. et al. (2004) Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation110: 1061-1068.
15.
Olsson, A.G., Schwartz, G.G., Szarek, M., Sasiela, W.J., Ezekowitz, M.D., Ganz, P. et al. (2005) High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J26: 890-896.
16.
Omland, T., Persson, A., Ng, L., O’Brien, R., Karlsson, T., Herlitz, J. et al. (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation106: 2913-2918.
17.
Pasceri, V., Patti, G., Nusca, A., Pristipino, C., Richichi, G. and Di Sciascio, G. ( 2004) Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study . Circulation110: 674-678.
18.
Plenge, J.K., Hernandez, T.L., Weil, K.M., Poirier, P., Grunwald, G.K., Marcovina, S.M. et al. (2002) Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction . Circulation106: 1447-1452.
19.
Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F.M., Moye, L.A., Goldman, S. et al. (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation98: 839-844.
20.
Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F. and Braunwald, E. ( 1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators . Circulation100: 230-235.
21.
Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, Cholesterol and Recurrent Events Trial investigators. N Engl J Med335: 1001-1009.
22.
Scandinavian Simvastatin Survival Study Group. ( 1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) . Lancet344: 1383-1389.
23.
Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D. et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama285: 1711-1718.
24.
Strandberg, T.E., Vanhanen, H. and Tikkanen, M.J. ( 1999) Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet353: 118-119.
25.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Longterm Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med339: 1349-1357.
